Assessing health state utilities in elderly patients at cardiovascular risk.

PubWeight™: 2.12‹?› | Rank: Top 2%

🔗 View Article (PMID 16751323)

Published in Med Decis Making on June 05, 2006

Authors

Wolfgang C Winkelmayer1, Joshua S Benner, Robert J Glynn, Sebastian Schneeweiss, Philip S Wang, M Alan Brookhart, Raisa Levin, Joseph D Jackson, Jerry Avorn

Author Affiliations

1: Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02120, USA. wwinkelmayer@partners.org

Articles by these authors

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA (2003) 34.83

Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA (2004) 22.38

Variable selection for propensity score models. Am J Epidemiol (2006) 10.68

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet (2009) 10.52

A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol (2005) 8.77

Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65

Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med (2005) 8.44

Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32

High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology (2009) 7.40

A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol (2005) 7.31

Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19

Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA (2008) 6.63

Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J (2004) 6.57

Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol (2005) 6.20

Trends in suicide ideation, plans, gestures, and attempts in the United States, 1990-1992 to 2001-2003. JAMA (2005) 5.70

A randomized study of how physicians interpret research funding disclosures. N Engl J Med (2012) 5.47

Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 5.25

Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 5.13

Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med (2014) 4.99

Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol (2003) 4.95

Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA (2011) 4.73

Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol (2006) 4.70

Self-management education programs in chronic disease: a systematic review and methodological critique of the literature. Arch Intern Med (2004) 4.68

Full coverage for preventive medications after myocardial infarction. N Engl J Med (2011) 4.51

The comparative safety of analgesics in older adults with arthritis. Arch Intern Med (2010) 4.47

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet (2012) 4.46

Habitual caffeine intake and the risk of hypertension in women. JAMA (2005) 4.46

Suicide risk during antidepressant treatment. Am J Psychiatry (2006) 4.41

Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 4.40

Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation (2010) 4.37

New FDA breakthrough-drug category--implications for patients. N Engl J Med (2014) 4.30

Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst (2002) 4.16

Telephone screening, outreach, and care management for depressed workers and impact on clinical and work productivity outcomes: a randomized controlled trial. JAMA (2007) 4.11

HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (2010) 4.07

Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med (2002) 4.07

Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses' Health Study. J Am Coll Cardiol (2009) 3.99

A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol (2011) 3.98

Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA (2010) 3.85

Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol (2007) 3.82

The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med (2010) 3.78

Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med (2006) 3.75

The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med (2006) 3.64

Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med (2014) 3.62

Altitude and all-cause mortality in incident dialysis patients. JAMA (2009) 3.62

Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med (2010) 3.57

The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiol Psichiatr Soc (2009) 3.55

Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology (2006) 3.54

Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry (2006) 3.47

Individual and societal effects of mental disorders on earnings in the United States: results from the national comorbidity survey replication. Am J Psychiatry (2008) 3.45

Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ (2013) 3.43

The quality of pharmacologic care for vulnerable older patients. Ann Intern Med (2004) 3.34

Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol (2005) 3.33

Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ (2007) 3.30

The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med (2011) 3.27

Rethinking the use of physicians as hired expert lecturers. Ann Intern Med (2014) 3.22

Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. Eur Heart J (2007) 3.21

Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med (2005) 3.19

Drug-review deadlines and safety problems. N Engl J Med (2008) 3.16

Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med (2013) 3.13

Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation (2009) 3.09

Balancing innovation, access, and profits--market exclusivity for biologics. N Engl J Med (2009) 3.08

Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.04

High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation (2013) 3.03

Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA (2011) 3.02